N
ACET icon

Nuveen’s Adicet Bio ACET Stock Holding History

Nuveen’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,665
Closed -$965K – 3329
2024
Q1 		$965K Buy
25,665
+13,552
+112% +$561K ﹤0.01% 2722
2023
Q4 		$366K Buy
12,113
+1,938
+19% +$42.3K ﹤0.01% 3103
2023
Q3 		$223K Sell
10,175
-60
-0.6% -$2.12K ﹤0.01% 3021
2023
Q2 		$398K Buy
10,235
+4,317
+73% +$381K ﹤0.01% 2967
2023
Q1 		$545K Sell
5,918
-333
-5% -$41.8K ﹤0.01% 2789
2022
Q4 		$894K Sell
6,251
-802
-11% -$200K ﹤0.01% 2724
2022
Q3 		$1.6M Buy
7,053
+436
+7% +$111K ﹤0.01% 2518
2022
Q2 		$1.55M Buy
6,617
+1,517
+30% +$333K ﹤0.01% 2573
2022
Q1 		$1.23M Buy
5,100
+1,799
+54% +$414K ﹤0.01% 2726
2021
Q4 		$750K Sell
3,301
-807
-20% -$139K ﹤0.01% 2951
2021
Q3 		$473K Buy
4,108
+227
+6% +$28.2K ﹤0.01% 3176
2021
Q2 		$639K Buy
+3,881
New +$791K ﹤0.01% 3129
2019
Q4 		– Sell
-358
Closed -$354K – 3237
2019
Q3 		$354K Hold
358
– – ﹤0.01% 3024
2019
Q2 		$409K Buy
+358
New +$325K ﹤0.01% 3065

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Nuveen's ACET Position: Q2 2024 in Review

Nuveen sold out of Adicet Bio (ACET) in Q2 2024, closing a stake of 25,665 shares — an estimated $965K sold.

Nuveen first reported a position in ACET in Q2 2019 and held it in 14 quarters. The position peaked at $1.6M in Q3 2022. 86 funds tracked by Wall St. Rank hold ACET as of Q2 2024.

  • Nuveen reported no remaining Adicet Bio position as of Q2 2024 after selling out during the quarter.
  • Nuveen sold 25,665 Adicet Bio shares in Q2 2024, an estimated $965K.
  • Nuveen first reported a position in Adicet Bio in Q2 2019 and held it in 14 quarters.
  • Nuveen's Adicet Bio position peaked at $1.6M in Q3 2022.
  • 86 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.